ArticleRadiation and environmental biophysics2014
Sex differences in the incidence of chronic myeloid leukemia.
Article in Radiation and environmental biophysics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 46 citations in OpenAlex.
- Beyond XX and XY, Understanding Sex Differences in Leukemia.Medical sciences (Basel, Switzerland) · 2026Review
- Antiviral Therapy and Hepatitis B Reactivation Outcomes in Chronic Myeloid Leukemia Treated with Tyrosine Kinase Inhibitors: A Retrospective Cohort Study.Oman medical journal · 2026Article
- Long-term outcomes of Qing-Dai-induced pulmonary arterial hypertension.ERJ open research · 2025Article
- Cytogenetic Profile of Chromosomal Aberrations in Leukemia Using the Fluorescence In Situ Hybridization (FISH) Method at a Tertiary Institution in Gauteng Province.Diagnostics (Basel, Switzerland) · 2025Article
- Hesperetin increases membrane progesterone receptor expression in human myeloid leukemia cells and reduces ROS.Medical oncology (Northwood, London, England) · 2025Article
- Review
- Sex and Gender in Myeloid and Lymphoblastic Leukemias and Multiple Myeloma: From Molecular Mechanisms to Clinical Outcomes.Current oncology (Toronto, Ont.) · 2025Review
- Secular trend in disease burden of leukemia and its subtypes in China from 1990 to 2019 and its projection in 25 years.Annals of hematology · 2023Article
- Gender differences in leukemia outcomes based on health care expenditures using estimates from the GLOBOCAN 2020.Archives of public health = Archives belges de sante publique · 2023Article
- Natural Killer Cell-Mediated Immunotherapy for Leukemia.Cancers · 2022Review
- Polymorphisms in the CYP2A6 and ABCC4 genes are associated with a protective effect on chronic myeloid leukemia in the Brazilian Amazon population.Molecular genetics & genomic medicine · 2021Article
- Definition, Epidemiology, Pathophysiology, and Essential Criteria for Diagnosis of Pediatric Chronic Myeloid Leukemia.Cancers · 2021Review
- Prospects for achieving treatment-free remission in chronic myeloid leukaemia.British journal of haematology · 2020Review
- Comprehensive analyses of safety and efficacy toward individualizing imatinib dosage in patients with chronic myeloid leukemia.International journal of hematology · 2020Article
- Chronic myeloid leukemia stem cells.Leukemia · 2019Review
- Sexual dimorphism in solid and hematological malignancies.Seminars in immunopathology · 2019Review
- Impact of Additional Chromosomal Aberrations on the Disease Progression of Chronic Myelogenous Leukemia.Frontiers in oncology · 2019Article
- CDA gene silencing regulated the proliferation and apoptosis of chronic myeloid leukemia K562 cells.Cancer cell international · 2018Article
- Defining AML and MDS second cancer risk dynamics after diagnoses of first cancers treated or not with radiation.Leukemia · 2016Article
- Transmission of CML or of t(9; 22) and BCR/ABL? They are not the same.Bone marrow transplantation · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 5 institutions in 3 countries.
Funding
Abstract
The incidence of chronic myeloid leukemia (CML), which is caused by BCR/ABL chimeric oncogene formation in a pluripotent hematopoietic stem cell (HSC), increases with age and exposure to ionizing radiation. CML is a comparatively well-characterized neoplasm, important for its own sake and useful for insights into other neoplasms. Here, Surveillance, Epidemiology and End Results (SEER) CML data are analyzed after considering possible misclassification of chronic myelo-monocytic leukemia as CML. For people older than 25 years, plots of male and female CML log incidences versus age at diagnosis are approximately parallel straight lines with males either above or to the left of females. This is consistent with males having a higher risk of developing CML or a shorter latency from initiation to diagnosis of CML. These distinct mechanisms cannot be distinguished using SEER data alone. Therefore, CML risks among male and female Japanese A-bomb survivors are also analyzed. The present analyses suggest that sex differences in CML incidence more likely result from differences in risk than in latency. The simplest but not the sole interpretation of this is that males have more target cells at risk to develop CML. Comprehensive mathematical models of CML could lead to a better understanding of the role of HSCs in CML and other preleukemias that can progress to acute leukemia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.